Error-Proof Entry, Expert Positioning, and Exploding Growth
02-Jun-2012 | News-Press Release
Your Advantage
  The potential medical advances made possible from the use of embryonic stem  cells (ESC) are huge. These stem cells are able to develop into any of over 200  different cell types. So it’s no surprise that the scientific research community  is enthusiastically exploring all possibilities.  http://www.bharatbook.com/stem-cells-market-research-reports/error-proof-entry-expert-positioning-and-exploding-growth-in-embryonic-stem-cell-products.html
  
  And where there is significant and growing interest from scientists, there is an  opportunity for a company like yours to increase revenue from supplying stem  cell products. There is no doubt it’s an exciting market in which to expand your  product range. But with embryonic stem cells there are serious market entry  barriers to consider – namely a complex intellectual property scene. 
  This report will help you understand the market entry challenges you face and  give you the expert advice to overcome them. Use it to out-compete your rivals  in this expanding and highly profitable market. Market Analysis 
  
  An Expanding and Highly Profitable Market
  Embryonic stem cells (hESCs) are stem cells derived from the inner cell mass  of a blastocyst, which is a stage reached four to five days post-fertilization.  Embryonic stem cells are the most pluripotent of all stem cell types and can  develop into over 200 different cell types of the human body. 
  
  Human embryonic stem cells were first derived from mouse embryos in 1981 by  Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995,  the first successful culturing of embryonic stem cells from non-human primates  occurred at the University of Wisconsin-Madison. Another breakthrough followed  at the University of Wisconsin-Madison in November 1998 when a group led by Dr.  James Thomson developed a technique to isolate and grow hESCs derived from human  blastocysts. Federal funds to support hESC research became available on August  9, 2001, when President Bush announced his decision regarding federal funding  for hESC research. 
  
  Because of their plasticity and unlimited capacity for self-renewal, hESCs have  been proposed for use in wide range of applications, including toxicology  testing, tissue engineering, cellular therapies, and basic stem cell biology  research. Of particular interest to the medical community is the potential for  use of hESCs to heal tissues with naturally limited capacity for renewal, such  as the human heart, liver and brain. However, human embryonic stem cell research  is heavily encumbered by patents held by the University of Wisconsin's Wisconsin  Alumni Research Foundation (WARF), which creates significant challenges for  companies seeking to develop new products.
  
  This market research report explores the complex IP landscape affecting  development of embryonic stem cell products, providing clear guidance for  companies entering or already within the market, from collaborating with WARF to  less costly alternatives, such as circumventing the claims, conducting research  off-shore, and developing embryonic stem cell products for other species. This  report will give you a fuller, more complete understanding of the complex IP  situation in the embryonic stem cell market. 
  
  This market report also recognizes that a wide range of products and services  are needed to support the active and well-funded embryonic stem cell research  community. 
  
  You’ll learn:
  • Key advances in embryonic stem cell research
  • A breakdown of embryonic stem cell research applications, including shared  priorities and priorities by segment 
  • Embryonic stem cell patent analysis
  • Historical and future growth projections for the embryonic stem cell market
  • Competitive analysis of providers of embryonic stem cell research tools
  • Overview of specialty pharma companies developing embryonic stem cell  therapies
  • Overview of toxicology testing legislation impacting use of embryonic stem  cells in toxicology applications
  • A breakdown of embryonic stem cell research product categories
  • Suggestions for novel embryonic stem cell research products, including cells,  kits, assays, media and reagents
  • Guidance for companies that wish to offer embryonic stem cell products
  • And much more
  
  The report is the only product available anywhere that provides specific  intelligence, guidance, and strategies for research supply companies competing  within the expanding and highly profitable embryonic stem cell product market. 
  
  Table of Contents
  I. Background
  A. Human Embryonic Stem Cells (hESC)
  B. Brief History
  C. Use in Treatment of Disease
  D. Human Embryonic Stem Cell Line Availability
  
  II. Available Stem Cell Lines
  A. NIH Registry Approved
  B. Sources of Additional Published hESC Lines
  C. Sources of Additional Unpublished hESC Lines
  
  For more information kindly visit : 
  Error-Proof Entry, Expert Positioning, and Exploding Growth
  
  Or
  
  Bharat Book Bureau
  Tel: +91 22 27810772 / 27810773
  Fax: + 91 22 27812290
  Email: info@bharatbook.com
  Website: www.bharatbook.com
  Follow us on twitter:  http://twitter.com/#!/Sandhya3B
  https://twitter.com/#!/bharatbook
This release was submitted by a Newsbox user.
Any communication related to the content of this release should be sent to the release submitter.
Author Info
Tag Cloud
Categories
More Releases
- Research on Global and China Epoxy Resin Industry Chain Report
 - The Geothermal Energy Market 2012-2022
 - Adhesives and Sealants: Global Markets
 - Dermatological Drugs: World Market Prospects 2012-2022
 - The Electric and Range Extended Electric Light-Vehicle Report
 - India Urban & Industrial Waste to Energy Market
 - Understanding Russia's Regional Health Markets
 - 2012 Deep Research Report on China Wind Bearing Industry
 - Top 1000 Advertising Agents (European)
 - HNWI Asset Allocation in Switzerland to 2016
 
		


